Companies › Kali Therapeutics
2 active drug programs in 2 registered trials: 2 Phase 1; Immunology; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| KT501 Monoclonal antibody targeting CD19, BCMA and CD3 to deplete B cells and plasma cells | CD19, BCMA, CD3 | Phase 1 | Rheumatoid Arthritis (RA) | Feb 2027 |
| KT502 Monoclonal antibody targeting CD19 and CD3 for B cell depletion | CD19, CD3 | Phase 1 | Rheumatoid Arthritis (RA) | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07234773 | KT501 | Phase 1 | Rheumatoid Arthritis (RA) | Immunology | Feb 2027 |
| NCT07564154 | KT502 | Phase 1 | Rheumatoid Arthritis (RA) | Immunology | Dec 2027 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.